RCM
BCRX icon

RA Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

RA Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158M Hold
15,827,186
– – 1.38% 19
2026
Q1 		$151M Hold
15,827,186
– – 1.6% 16
2025
Q4 		$123M Buy
+15,827,186
New +$114M 1.26% 19
2019
Q2 		– Sell
-8,659,983
Closed -$70.5M – 26
2019
Q1 		$70.5M Sell
8,659,983
-2,000,366
-19% -$17.1M 3.04% 10
2018
Q4 		$86M Buy
10,660,349
+1,425,657
+15% +$11.1M 5.01% 5
2018
Q3 		$70.5M Buy
9,234,692
+2,250,000
+32% +$15.1M 3.77% 7
2018
Q2 		$40M Hold
6,984,692
– – 2.6% 15
2018
Q1 		$33.3M Hold
6,984,692
– – 2.55% 13
2017
Q4 		$34.3M Hold
6,984,692
– – 2.87% 12
2017
Q3 		$36.6M Buy
6,984,692
+1,822,450
+35% +$9.33M 3.31% 11
2017
Q2 		$28.7M Buy
5,162,242
+1,672,447
+48% +$10.2M 3.29% 10
2017
Q1 		$29.3M Buy
3,489,795
+500,000
+17% +$3.48M 3.6% 6
2016
Q4 		$18.9M Hold
2,989,795
– – 2.68% 10
2016
Q3 		$13.2M Hold
2,989,795
– – 1.36% 17
2016
Q2 		$8.49M Hold
2,989,795
– – 1.18% 19
2016
Q1 		$8.46M Sell
2,989,795
-104,269
-3% -$462K 1.08% 26
2015
Q4 		$31.9M Buy
3,094,064
+1,897,461
+159% +$18.9M 3.16% 8
2015
Q3 		$13.6M Sell
1,196,603
-1,408,758
-54% -$18.8M 1.96% 19
2015
Q2 		$38.9M Sell
2,605,361
-4,321,256
-62% -$49.1M 3.91% 8
2015
Q1 		$62.5M Sell
6,926,617
-123,739
-2% -$1.28M 6.21% 4
2014
Q4 		$85.7M Sell
7,050,356
-18,803
-0.3% -$208K 9.21% 2
2014
Q3 		$69.1M Buy
7,069,159
+3,870,630
+121% +$47.4M 8.17% 3
2014
Q2 		$40.8M Sell
3,198,529
-1,148,927
-26% -$11.2M 4.12% 9
2014
Q1 		$46M Hold
4,347,456
– – 3.3% 13
2013
Q4 		$33M Sell
4,347,456
-1,497,244
-26% -$9.48M 3.85% 10
2013
Q3 		$42.5M Buy
+5,844,700
New +$29.6M 4.44% 9

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

RA Capital Management's BCRX Position: Q2 2026 in Review

RA Capital Management held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 15,827,186 shares worth $158M. The position accounts for 1.38% of the portfolio, ranked #19.

RA Capital Management first reported a position in BCRX in Q3 2013 and has held it in 26 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • RA Capital Management held 15,827,186 shares of BioCryst Pharmaceuticals worth $158M as of Q2 2026.
  • RA Capital Management left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up 1.38% of RA Capital Management's portfolio in Q2 2026, its #19 holding.
  • RA Capital Management first reported a position in BioCryst Pharmaceuticals in Q3 2013 and has held it in 26 quarters since.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.